Premium
The Road From Discovery to Clinic: Adiponectin as a Biomarker of Metabolic Status
Author(s) -
Kusminski C M,
Scherer P E
Publication year - 2009
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2009.155
Subject(s) - adiponectin , biomarker , clinical pharmacology , context (archaeology) , medicine , psychological intervention , biomarker discovery , metabolic syndrome , bioinformatics , pharmacology , biology , obesity , insulin resistance , proteomics , psychiatry , paleontology , biochemistry , gene
Biomarkers are globally used to monitor clinical responses to therapeutic and lifestyle interventions. The adipocyte‐derived hormone adiponectin is recognized as a promising new biomarker owing to its many associations with components of the metabolic syndrome. The study described by Wagner and colleagues in this issue offers a first example of how a large‐scale effort in the context of a cross‐company collaborative study in the pharmaceutical industry can offer a powerful tool for the further validation of a new biomarker in the context of pharmacological intervention with peroxisome proliferator‐activated receptor‐γ (PPAR‐γ) agonists. 1 Clinical Pharmacology & Therapeutics (2009) 86 6, 592–595. doi: 10.1038/clpt.2009.155